ORIBÁTIDOS PRIMITIVOS DE MURCIA (ACARI), II

In this paper the study about Primitive Oribatid Mites in Murcia (Spain) is completed. The great part of 25 species founded have never been recorded in the province, three of these species and two general, Ctenacarus and Krisvoluiskiella, are new records for the lberian Peninsula. A new subgenera, Cosmochthonius (Microchthonius), with the species Cosmochihonius (Microchihonius) ruizi, and another new species, Bursoplophora Nisularis, are described.Como continuación de los estudios que sobre Oribátidos se llevan a cabo en la provincia de Murcia, en este trabajo se publica una lista con 25 especies de Oribátidos Primitivos encontrados en ella. La mayoría no estaban citadas en la provincia y tres han resultado también nuevas citas para la Península Ibérica, así como los géneros Ctenacarus y Krivolutskiella. Se describe, además, un nuevo subgénero, Cosmochthonius (Microchthonius) ruizi, y otra nueva especie, Bursoplophora insularis

Resting and exercise haemodynamic characteristics of patients with advanced heart failure and preserved ejection fraction

Aims: This study aimed to describe haemodynamic features of patients with advanced heart failure with preserved ejection fraction (HFpEF) as defined by the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Methods and results: We used pooled data from two dedicated HFpEF studies with invasive exercise haemodynamic protocols, the REDUCE LAP-HF (Reduce Elevated Left Atrial Pressure in Patients with Heart Failure) trial and the REDUCE LAP-HF I trial, and categorized patients according to advanced heart failure (AdHF) criteria. The well-characterized HFpEF patients were considered advanced if they had persistent New York Heart Association classification of III–IV and heart failure (HF) hospitalization < 12 months and a 6 min walk test distance < 300 m. Twenty-four (22%) out of 108 patients met the AdHF criteria. On evaluation, clinical characteristics and resting haemodynamics were not different in the two groups. Patients with AdHF had lower work capacity compared with non-advanced patients (35 ± 16 vs. 45 ± 18 W, P = 0.021). Workload-corrected pulmonary capillary wedge pressure normalized to body weight (PCWL) was higher in AdHF patients compared with non-advanced (112 ± 55 vs. 86 ± 49 mmHg/W/kg, P = 0.04). Further, AdHF patients had a smaller increase in cardiac index during exercise (1.1 ± 0.7 vs. 1.6 ± 0.9 L/min/m2, P = 0.028). Conclusions: A significantly higher PCWL and lower cardiac index reserve during exercise were observed in AdHF patients compared with non-advanced. These differences were not apparent at rest. Therapies targeting the haemodynamic compromise associated with advanced HFpEF are needed

RB but not R‐HCVAD is a feasible induction regimen prior to auto‐HCT in frontline MCL: results of SWOG Study S1106

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/136294/1/bjh14480_am.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/136294/2/bjh14480.pd

RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106

Aggressive induction chemotherapy followed by autologous haematopoietic stem cell transplant (auto-HCT) is effective for younger patients with mantle cell lymphoma (MCL). However, the optimal induction regimen is widely debated. The Southwesterm Oncology Group S1106 trial was designed to assess rituximab plushyperCVAD/MTX/ARAC (hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone, alternating with high dose cytarabine and methotrexate) (RH) versus rituximab plus bendamustine (RB) in a randomized phase II trial to select a pre-transplant induction regimen for future development. Patients had previously untreated stage III, IV, or bulky stage II MCL and received either 4 cycles of RH or 6 cycles of RB, followed by auto-HCT. Fifty-three of a planned 160 patients were accrued; an unacceptably high mobilization failure rate (29%) on the RH arm prompted premature study closure. The estimated 2-year progression-free survival (PFS) was 81% vs. 82% and overall survival (OS) was 87% vs. 88% for RB and RH, respectively. RH is not an ideal platform for future multi-centre transplant trials in MCL. RB achieved a 2-year PFS of 81% and a 78% MRD negative rate. Premature closure of the study limited the sample size and the precision of PFS estimates and MRD rates. However, RB can achieve a deep remission and could be a platform for future trials in MCL

Oribatidos inferiores (Acari, Oribatida, Macropylina) de Andalucia, con descripción de tres nuevas especies

[EN] A list of 40 lower oribatid mites (Macropylina) species collected in Andalusia (South of Spain), with their biogeographical distribution, is presented. Three new species are described: Sellnickochthonius anonymus, Sellnickochthonius fuentesi and Lohmannia semibarbulata spp. n. Two other species, Cosmochthonius asiaticus Gordeeva, 1980 and Paralycus pyrigerus (Berlese, 1905), are recorded for the fist time for the Iberian Peninsula.[ES] Se listan las 40 especies de oribátidos inferiores (Macropylina) encontrados en Andalucía, dándose para cada una de ellas su actual distribución biogeográfica. Además se describen tres nuevas especies: Sellnickochthonius anonymus, Sellnickochthonius fuentesi y Lohmannia semibarbulata spp. n. También se citan por primera vez para la Península Ibérica Cosmochthonius asiaticus Gordeeva, 1980 y Paralycus pyrigerus (Berlese, 1905).Peer reviewe

Nuevas especies de Oribatulidae y Passalozetidae (Acari, Oribatida) de España meridional

[EN] Three new species from southern Spain are described: Passalozetes onubensis n. sp., Oribatula torrijosi n. sp. and Zygoribatula dactylaris n. sp. They were collected in four Andalusian provinces: Huelva, Sevilla, Granada and Almería.[ES] Se describen tres nuevas especies de Oribátidos, recolectadas en el sur de España, procedentes de muestras de cuatro provincias de Andalucía: Huelva, Sevilla, Granada y Almería: Passalozetes onubensis n. sp., Oribatula torrijosi n. sp. y Zygoribatula dactylaris n. sp.Peer reviewe

Pediatric Oral/Maxillofacial Soft Tissue Sarcomas: A Clinicopathologic Report of Four Cases

Pediatric soft tissue sarcomas of the oral/maxillofacial region are rare neoplasms that present significant difficulty with respect to treatment and local control measures. We report four cases of pediatric oral/maxillofacial soft tissue sarcomas from our tertiary care pediatric hospital and emphasize the rarity of these malignancies and the challenges encountered in treating these lesions, and suggest areas for further research. We conclude that multimodal therapy and interdisciplinary cooperation are paramount to successful management of these lesions

Reducing the Burden of Oncology Chemoradiotherapy and Radiation Exposure From Diagnostic Imaging by Utilizing Targeted Immunotherapy in Children, Adolescents and Young Adults With Hodgkin Lymphoma

Background and Aims: Significant chronic health conditions continues to increase over time among pediatric, adolescent, and young adult (CAYA) classical Hodgkin lymphoma (cHL) survivors. Targeting the tumor microenvironment (TME) and tumor-specific antigens is emerging as effective and safe treatments for cHL patients. Recently, we completed a phase 2 trial evaluating the use of antibody-drug conjugate targeting CD30 (brentuximab vedotin, Bv) and regulatory B-cells (rituximab, RTX) to risk-adapted chemotherapy in newly diagnosed cHL CAYA patients. The combination was safe and resulted in significant reduction to toxic chemotherapy and radiation therapy (RT), while keeping superior outcomes (5-year OS/EFS 100%; Hochberg/Cairo, JITC 2022). Adding the checkpoint inhibitor nivolumab to chemoimmunotherapy with RTX + Bv may allow further anthracycline dose reduction and RT in intermediate-/high-risk cHL in CAYA. Methods: This is a multicenter study for patients with intermediateand high-risk cHL. Intermediate-risk cHL patients receive 2 cycles of Bv, doxorubicin, vinblastine, dacarbazine, and RTX (Bv-AVD-R). Rapid early responders (RER) or slow early responders (SER) by FDG-PET scan receive 2 or 4 cycles of Bv, vinblastine, dacarbazine, nivolumab, and RTX (Bv-NVD-R), respectively. High-risk cHL patients receive 2 cycles of Bv-AVD-R. RERs by FDG-PET scan receive 4 cycles of Bv-NVD-R; SERs receive 2 cycles of Bv, nivolumab, doxorubicin, vinblastine, dacarbazine and RTX (Bv-NAVD-R), followed by 4 cycles of Bv-NVD-R. RT will be given to SER patients not achieving CR. Patients age ≥ 3 and ≤ 39 years will be enrolled with a primary objective to assess safety/feasibility of adding nivolumab to chemoimmunotherapy with RTX + Bv in intermediate-/high-risk cHL. Results: Two patients have been enrolled to date and have had no DLT. Accrual is ongoing. Additional results will be presented at the meeting Conclusions: Targeting the TME (regulatory B-cells) and PD1/PD-L1 axis is a promising approach in CAYA with cHL. (NCT05253495)